NRAS and acute myeloid leukemia: NPM1 had the highest mutation frequency (n = 18, 25.4%), followed by DNMT3A (n = 17, 23.9%), FLT3 (n = 17, 23.9%), IDH1/2 (n = 17, 23.9%), RUNX1 (n = 8, 11.3%), NRAS/KRAS (n =7, 9.9%), TET2 (n = 4, 5.6%), TP53 (n = 4, 5.6%).Forty-eight patients had AML relapse.